Online citations, reference lists, and bibliographies.

Therapeutic Mechanisms Of Classic Hallucinogens In The Treatment Of Addictions: From Indirect Evidence To Testable Hypotheses.

Michael P. Bogenschutz, Jessica M Pommy
Published 2012 · Medicine, Chemistry
Cite This
Download PDF
Analyze on Scholarcy
Share
Alcohol and drug addiction are major public health problems, and existing treatments are only moderately effective. Although there has been interest for over half a century in the therapeutic use of classic hallucinogens to treat addictions, clinical research with these drugs was halted at an early stage in the early 1970s, leaving many fundamental questions unanswered. In the past two decades, clinical research on classic hallucinogens has resumed, although addiction treatment trials are only now beginning. The purpose of this paper is to provide a targeted review of the research most relevant to the therapeutic potential of hallucinogens, and to integrate this information with current thinking about addiction and recovery. On the basis of this information, we present a heuristic model which organizes a number of hypotheses that may be tested in future research. We conclude that existing evidence provides a convincing rationale for further research on the effects of classic hallucinogens in the treatment of addiction.
This paper references
10.1111/j.1530-0277.1996.tb01686.x
A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment.
D I Kabel (1996)
10.1001/jama.1970.03170240060010
The experimental use of psychedelic (LSD) psychotherapy.
Walter N. Pahnke (1970)
The effects of psychedelic (LSD) therapy on values, personality, and behavior.
Catharine H. Savage (1966)
10.1001/archpsyc.1997.01830200024004
Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial.
Jack R. Cornelius (1997)
Wilbourne. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders
P.L.W.R. Miller (2002)
10.1177/0960327107087802
Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review
Romualdas Mačiulaitis (2008)
10.1016/j.biopsych.2007.05.028
Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors
Sungho Maeng (2008)
Psilocybin in smoking cessation: A pilot study
M. W. Johnson (2010)
Alcoholics Anonymous and Other 12-Step Groups
Chad D. Emrick (1999)
10.1186/1471-244X-8-22
Five-Factor Model personality profiles of drug users
Antonio Terracciano (2008)
10.1016/0006-3223(94)91215-7
Serotonin and alcohol intake, abuse, and dependence: Findings of animal studies
David Lemarquand (1994)
10.1016/S0006-3223(99)00230-9
Antidepressant effects of ketamine in depressed patients
Robert M. Berman (2000)
10.2307/1906744
Peyote Religion: A History
Omer Call Stewart (1987)
10.1016/j.drugalcdep.2004.09.004
Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis.
Marta Torrens (2005)
10.1016/j.jep.2005.04.022
Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas.
Hesham R El-Seedi (2005)
10.1176/ajp.125.10.1352
A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics.
Leo E. Hollister (1969)
10.1080/02791072.1977.10472060
Psychedelic Drug (DPT)-Assisted Psychotherapy with Alcoholics: A Controlled Study
John C. Rhead (1977)
10.1016/S0278-5846(03)00081-2
Drug craving and addiction: integrating psychological and neuropsychopharmacological approaches
Ingmar H. A. Franken (2003)
10.1300/J020v21n04_02
Life-Changing Experiences, Spirituality and Religiousness of Persons Entering Treatment for Alcohol Problems
Elizabeth A. R. Robinson (2003)
10.1177/0269881108094300
Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later
Roland R Griffiths (2008)
10.1080/09595230601036960
Imaging stress- and cue-induced drug and alcohol craving: association with relapse and clinical implications.
Rajita Sinha (2007)
10.1093/cercor/13.8.870
In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents.
Marta Puig (2003)
Counseling
W. A. Richards (2012)
10.1097/00005053-197002000-00003
Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study.
Walter T. Bowen (1970)
10.1080/02791072.2007.10399860
Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence
Evgeny Krupitsky (2007)
10.1016/S0893-133X(98)00108-0
5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride
Franz X. Vollenweider (1999)
10.1177/009164718301100406
Spiritual Well-Being: Conceptualization and Measurement
Craig W. Ellison (1983)
10.15288/jsad.2007.68.641
Cocaine craving as a predictor of treatment attrition and outcomes after residential treatment for cocaine dependence.
Damaris J. Rohsenow (2007)
10.1111/j.1360-0443.2006.01423.x
A review of the acute subjective effects of MDMA/ecstasy.
Chelsea A. Baylen (2006)
Possible pharmacological probes for predicting and preventing relapse in treated alcoholics.
Naranjo Ca (1991)
10.1007/s00213-002-1002-9
Ondansetron reduces the craving of biologically predisposed alcoholics
Bankole A Johnson (2002)
10.1177/0013124582015001005
Counseling
Joan P. Avis (1982)
10.1007/978-1-4899-1678-5_13
Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers.
Claudio A. Naranjo (1989)
10.1038/sj.npp.1300711
Behavioral Tolerance to Lysergic Acid Diethylamide is Associated with Reduced Serotonin-2A Receptor Signaling in Rat Cortex
Paul J Gresch (2005)
Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
Neil S. Buckholtz (1990)
10.1016/s0084-3970(08)70128-2
Prevalence and Co-occurrence of Substance Use Disorders and Independent Mood and Anxiety Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions
John A. Talbott (2006)
10.15288/jsa.2006.67.562
Examining the effects of alcoholism typology and AA attendance on self-efficacy as a mechanism of change.
Michael P. Bogenschutz (2006)
10.1093/shm/hkl039
‘Hitting Highs at Rock Bottom’: LSD Treatment for Alcoholism, 1950–1970
Erika Dyck (2006)
10.1111/j.1530-0277.2007.00499.x
A role for spiritual change in the benefits of 12-step involvement.
Sarah E. Zemore (2007)
10.1177/0269881112439253
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Teri Suzanne Krebs (2012)
10.1080/00221309.1969.9710481
Personality change in LSD users.
John Bottrill (1969)
A program for treatment of alcoholism: LSD
A. Hoffer (1967)
10.1001/archpsyc.63.8.856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Carlos A. Zarate (2006)
10.1177/0269881106063271
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
Glenn J. H. Dumont (2006)
10.1080/02791072.1968.10524522
The psychedelic experience--a new concept in psychotherapy.
John Neil Sherwood (1962)
10.15288/qjsa.1970.31.932
Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation.
Milan Tomsovic (1970)
What is motivational interviewing? Behav
S. Rollnick (1995)
10.1037/h0088594
Personality change associated with psychedelic (LSD) therapy: A preliminary report.
Robert E. Mogar (1964)
10.2190/DE.37.3.d
Alcohol Involvement and the Five-Factor Model of Personality: A Meta-Analysis
John M Malouff (2007)
10.1111/j.1749-6632.2000.tb06677.x
Development of novel medications for drug addiction. The legacy of an African shrub.
Stanley D. Glick (2000)
10.1300/J069v25n04_06
Personality Changes in Women Recovering from Substance-Related Dependence
Patricia D. Borman (2006)
10.4324/9780203393789
Varieties of Religious Experience
William James (1990)
10.2307/1384454
The Construction and Preliminary Validation of a Measure of Reported Mystical Experience
Ralph W. Jr Hood (1975)
10.1016/s0084-3970(10)79416-0
From In-Session Behaviors to Drinking Outcomes: A Causal Chain for Motivational Interviewing
Richard J. Frances (2011)
10.1016/j.pharmthera.2010.09.007
Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse.
George R. Breese (2011)
10.1073/pnas.0708862105
Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo
Cullen L. Schmid (2008)
10.1111/j.1530-0277.1996.tb05263.x
Efficacy of buspirone in alcohol dependence: a review.
T Malec (1996)
10.1016/j.drugalcdep.2010.03.024
Assessment of addiction severity among ritual users of ayahuasca.
Josep María Fábregas (2010)
10.1006/jrpe.2001.2326
Cracking the Plaster Cast: Big Five Personality Change during Intensive Outpatient Counseling
Ralph L. Piedmont (2001)
10.1016/S0740-5472(02)00275-1
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.
Evgeny Krupitsky (2002)
10.1016/j.bcp.2007.08.005
Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
Bankole A Johnson (2008)
A review of LSD treatment in alcoholism.
Faruk S. Abuzzahab (1971)
10.1192/bjp.bp.110.084178
Effects of lowered serotonin transmission on cocaine-induced striatal dopamine response: PET [¹¹C]raclopride study in humans.
Sylvia M. L. Cox (2011)
The adverse effects of hallucinogens from intramural perspective.
Ede Frecska (2006)
10.1016/j.pbb.2007.10.003
Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons
Gary A. Gudelsky (2008)
Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament.
John H. Halpern (2008)
Pharmacology of classical hallucinogens and related designer drugs
R. A. Glennon (2009)
Medications and Alcohol Craving
R. M. Swift (1999)
10.1177/0269881108093587
Human hallucinogen research: guidelines for safety
M A Johnson (2008)
10.1038/tp.2011.57
Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption
S Barak (2011)
10.1016/S0306-4603(98)00005-7
The relationship of NEO-PI performance to coping styles, patterns of use, and triggers for use among substance abusers.
Richard A. McCormick (1998)
10.1016/j.biopsych.2008.09.029
Family History of Alcohol Dependence and Initial Antidepressant Response to an N-methyl-D-aspartate Antagonist
Laura E. Phelps (2009)
10.1016/j.neubiorev.2011.03.005
5-HT receptors and reward-related behaviour: A review
Dave J. Hayes (2011)
10.4135/9781412964500.n199
Motivational interviewing.
Amanda White Gibson (2000)
10.1001/archpsyc.1967.01730290009002
LONG LASTING EFFECTS OF LSD ON NORMALS
William H. Mcglothlin (1967)
Mysticaltype experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months
R. Griffiths (2008)
Motivation for Change and Alcoholism Treatment
Carlo C. Diclemente (1999)
10.4414/smw.2007.11932
Ketamine and the potential role for rapid-acting antidepressant medications.
John H. Krystal (2007)
10.1016/j.pharmthera.2008.12.001
GDNF--a potential target to treat addiction.
Sebastien Carnicella (2009)
10.1016/S0740-5472(03)00118-1
Exploratory findings from the Reasons for Drinking Questionnaire.
William H. Zywiak (2003)
10.1111/j.1369-1600.2008.00136.x
Identifying the neural circuitry of alcohol craving and relapse vulnerability.
Andreas Heinz (2009)
10.1016/j.neuron.2007.01.008
Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior
Javier González-Maeso (2007)
My First Forty Years
B. Wilson (2000)
10.1002/jclp.20000
The phenomenon of quantum change.
William R. Miller (2004)
10.1016/j.biopsych.2009.08.038
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
Marije aan het Rot (2010)
Psychedelic Drugs Reconsidered
James B. Bakalar (1979)
Religion and Psychoactive Sacraments: A Bibliographic Guide
T. B. Roberts (1995)
10.1016/j.psychres.2004.07.013
Impact of different personality dimensions (NEO Five-Factor Inventory) on the outcome of alcohol-dependent patients 6 and 12 months after treatment
Miriam Bottlender (2005)
10.1016/j.comppsych.2008.09.003
Comorbidity and temporal ordering of alcohol use disorders and other psychiatric disorders: results from a Danish register-based study.
Trine Flensborg-Madsen (2009)
10.1186/1471-244X-3-1
Relationship between craving and personality in treatment-seeking women with substance-related disorders
Monica L. Zilberman (2003)
10.1176/appi.ajp.2010.10050755
Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.
Bankole A Johnson (2011)
10.1371/journal.pone.0014074
Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans
Matthew J. Baggott (2010)
Life Changing Experiences: An Analysis of 21st Century Martin Amis
Julia van Luijk (2011)
10.1037//0893-164X.14.3.257
Alcohol treatment, changes in coping skills, self-efficacy, and levels of alcohol use and related problems 1 year following treatment initiation.
Stephen A. Maisto (2000)
Religion and Psychoactive Sacraments: A Bibliographic Guide
T. B. Roberts (1995)
10.1523/JNEUROSCI.17-22-08828.1997
The Olivocerebellar Projection Mediates Ibogaine-Induced Degeneration of Purkinje Cells: A Model of Indirect, Trans-Synaptic Excitotoxicity
Elizabeth E O'Hearn (1997)
10.1525/maq.2000.14.4.521
Jesus, peyote, and the holy people: alcohol abuse and the ethos of power in Navajo healing.
J F Garrity (2000)
10.1007/s11920-007-0063-1
The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects
Sungho Maeng (2007)
10.1016/j.biopsych.2009.04.029
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
Rebecca B. Price (2009)
10.2307/2217211
Mysticism and Philosophy.
Ninian Smart (1960)
10.1300/J020V09N01_09
The Combination of Psychedelic and Aversive Approaches in Alcoholism Treatment
E. M. Krupitsky (1992)
10.1080/00332747.1963.11023344
Mescaline, LSD, Psilocybin, and Personality Change a Review†
Sanford M. Unger (1963)
10.1523/JNEUROSCI.1665-10.2010
Serotonin, But Not N-Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo
Cullen L. Schmid (2010)
10.4135/9781412953948.n413
Self efficacy.
Bissoondial Ootim (2000)
Medication development of ibogaine as a pharmacotherapy for drug dependence.
Deborah C. Mash (1998)
10.1016/B978-0-12-385506-0.00010-7
Role of the serotonergic system in alcohol dependence: from animal models to clinics.
Youssef Sari (2011)
10.1007/s00127-003-0597-4
Temporal sequencing of lifetime mood disorders in relation to comorbid anxiety and substance use disorders
Ron de Graaf (2003)
10.1159/000467979
DPT as an adjunct in psychotherapy of alcoholics.
S Grof (1973)
10.1037/a0020327
Linking "big" personality traits to anxiety, depressive, and substance use disorders: a meta-analysis.
Roman Kotov (2010)
10.1037/h0041593
Cognitive consequences of forced compliance.
Leon Festinger (1959)
10.1080/02791072.1998.10399709
Hallucinogenic drugs and plants in psychotherapy and shamanism.
Rebecca Metzner (1998)
10.1080/02791072.2009.10399905
Changes in Spirituality Among Ayahuasca Ceremony Novice Participants
Stephen Trichter (2009)
10.1176/appi.psychotherapy.1964.18.1.35
LSD IN PSYCHOTHERAPY.
Seymour Schoen (1964)
Theroetical aspects of LSD therapy
J. Buckman (1967)
10.5860/choice.35-1826
Self-Efficacy: The Exercise of Control
Albert Bandura (1997)
10.1111/j.1530-0277.2000.tb04648.x
Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype.
Helen M. Pettinati (2000)
10.1111/j.1471-4159.2008.05357.x
Serotonin (5-HT) induces glial cell line-derived neurotrophic factor (GDNF) mRNA expression via the transactivation of fibroblast growth factor receptor 2 (FGFR2) in rat C6 glioma cells.
Mami Tsuchioka (2008)
10.1111/j.1360-0443.2011.03593.x
Determining the relative importance of the mechanisms of behavior change within Alcoholics Anonymous: a multiple mediator analysis.
John F Kelly (2012)
10.1037/0022-3514.93.6.1080
Relations between personality and coping: a meta-analysis.
Jennifer K Connor-Smith (2007)
10.15288/qjsa.1966.27.469
A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior.
Reginald George Smart (1966)
10.1007/s00213-011-2358-5
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Roland R Griffiths (2011)
10.4088/JCP.v67n1110
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
Francisco A. Moreno (2006)
10.1001/jama.291.15.1887
Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.
Edward V Nunes (2004)
10.1016/j.arcped.2012.01.013
[Et al].
Pierre Cochat (2012)
10.1192/bjp.bp.107.041228
Brain dopamine response in human opioid addiction.
Mark R. C. Daglish (2008)
10.1073/pnas.0700436104
Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex
Jean-Claude Béı̈que (2007)
10.1037/a0025204
Dynamic effects of craving and negative affect on adolescent smoking relapse.
Rinka M P van Zundert (2012)
10.1002/jclp.20004
De profundis: spiritual transformations in Alcoholics Anonymous.
Alyssa A. Forcehimes (2004)
10.1097/00001756-199812010-00024
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
Franz X. Vollenweider (1998)
10.1016/j.drugalcdep.2009.07.016
Reactivity to laboratory stress provocation predicts relapse to cocaine.
Sudie E Back (2010)
10.1046/j.1360-0443.1995.9018712.x
Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems.
Claudio A. Naranjo (1995)
10.1080/02791072.1998.10399714
Treatment of alcoholism using psychedelic drugs: a review of the program of research.
Mariavittoria Mangini (1998)
10.1017/S1461145709000169
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
Sanjay J Mathew (2010)
10.1080/00952990701653818
A Comparison of General Self-Efficacy and Drinking Refusal Self-Efficacy in Predicting Drinking Behavior
Tian Po Oei (2007)
10.1207/s15473333thp3404_7
Ketamine Enhanced Psychotherapy: Preliminary Clinical Observations on Its Effectiveness in Treating Alcoholism
Eli Kolp (2006)
10.3109/16066359609010756
The Use of Hallucinogens in the Treatment of Addiction
John H. Halpern (1996)
10.1007/springerreference_121662
Glial Cell Line-Derived Neurotrophic Factor
Zoologie (2011)
10.1097/00004850-199409000-00004
Fluoxetine attenuates alcohol intake and desire to drink.
Claudio A. Naranjo (1994)
10.1016/j.neulet.2011.01.046
Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists
José L. Moreno (2011)
10.1038/nrn2884
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Franz X. Vollenweider (2010)
10.1097/00005053-196312000-00007
REACTIONS TO PSILOCYBIN ADMINISTERED IN A SUPPORTIVE ENVIRONMENT.
Timothy J. C. Leary (1963)
10.1300/J020v21n01_01
The Role of Religion, Spirituality and Alcoholics Anonymous in Sustained Sobriety
Lee Ann Kaskutas (2003)
A consensus statement on defining change talk
W. R. Miller (2006)
Peyote Hunt
B. Meyerhoff (1974)
10.1176/ajp.126.1.59
A clinical study of LSD treatment in alcoholism.
Annick Ludwig (1969)
10.1111/j.1465-3362.2011.00303.x
Relationship of relapse with impulsivity, novelty seeking and craving in male alcohol-dependent inpatients.
Cuneyt Evren (2012)
10.1016/j.biopsych.2004.05.009
Treatment of cocaine dependence and depression
Bruce J. Rounsaville (2004)
10.1080/02791072.2005.10399794
Report on Psychoactive Drug Use Among Adolescents Using Ayahuasca Within a Religious Context
Evelyn Doering-Silveira (2005)
10.1001/archgenpsychiatry.2010.116
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Charles S. Grob (2011)
10.1016/j.biopsych.2005.06.038
Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans
John H. Halpern (2005)
10.1073/pnas.0905884106
Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling
Kelly A Jones (2009)
10.1111/j.1530-0277.2007.00390.x
Heterogeneous effects of alcohol on dopamine release in the striatum: a PET study.
Karmen K. Yoder (2007)
10.1177/0269881111420188
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
Katherine A. MacLean (2011)
10.1093/alcalc/34.2.244
The role of serotonin in craving: from basic research to human studies.
Roberto Ciccocioppo (1999)
10.1001/archpsyc.1973.01750360040005
Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study.
Cathy Savage (1973)
10.1038/clpt.1992.85
Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers.
Claudio A. Naranjo (1992)
10.1080/00952990802455469
Traditional Medicine in the Treatment of Drug Addiction
Lin Lu (2009)
10.1037/0893-164X.10.2.90
A measure of religious background and behavior for use in behavior change research
Gerard J. Connors (1996)
10.1016/0146-6402(78)90002-4
Self-efficacy: Toward a unifying theory of behavioral change
Albert Bandura (1978)
10.1176/ajp.142.11.1259
The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence.
Edward J. Khantzian (1987)
10.1037/a0022282
Moderating effects of a craving intervention on the relation between negative mood and heavy drinking following treatment for alcohol dependence.
Katie A Witkiewitz (2011)
Self-efficacy
A. Bandura (1994)
10.1016/j.neubiorev.2009.11.009
Role of BDNF and GDNF in drug reward and relapse: A review
Udi E. Ghitza (2010)
10.1016/j.addbeh.2011.07.032
The role of self-efficacy in the treatment of substance use disorders.
Ronald M. Kadden (2011)
10.1111/j.1530-0277.2010.01362.x
Spirituality in recovery: a lagged mediational analysis of alcoholics anonymous' principal theoretical mechanism of behavior change.
John F Kelly (2011)
Psychedelic drugs and mystical experience.
Walter N. Pahnke (1969)
10.1001/jama.284.8.963
Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
Bankole A Johnson (2000)
10.1016/j.addbeh.2010.06.008
A personality-based description of maturing out of alcohol problems: extension with a five-factor model and robustness to modeling challenges.
Andrew K Littlefield (2010)
10.1111/j.1369-1600.2010.00251.x
Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.
Sebastien Carnicella (2010)
Five Factor correlates: A comparison of substance abusers and non-substance abusers
C. Dubey (2010)
10.1111/1467-9280.00137
Motivation for Change: Implications for Substance Abuse Treatment
Carlo C. Diclemente (1999)
10.1016/s0084-3970(08)79204-1
GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse
James C. Ballenger (2009)
10.1176/ajp.131.11.1247
Peyote in the treatment of alcoholism among American Indians.
B J Albaugh (1974)
10.1016/j.pnpbp.2007.07.009
AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes
Ce Zhang (2008)
10.1093/alcalc/34.2.254
Craving and relapse measurement in alcoholism.
Annelize Potgieter (1999)
10.1016/j.drugalcdep.2009.03.009
Daily ratings measures of alcohol craving during an inpatient stay define subtypes of alcohol addiction that predict subsequent risk for resumption of drinking.
David Oslin (2009)
10.1037/0022-3514.84.2.411
Big Five factors of personality and replicated predictions of behavior.
S. V. Paunonen (2003)
10.15288/jsad.2010.71.434
Negative affect, relapse, and Alcoholics Anonymous (AA): does AA work by reducing anger?
John F Kelly (2010)
10.1038/mp.2008.41
Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions
Bridget F. Grant (2009)
10.1016/j.bcp.2007.07.018
The behavioral pharmacology of hallucinogens.
William E Fantegrossi (2008)
10.1007/s00213-006-0457-5
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Roland R Griffiths (2006)
Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical cons
Walter N. Pahnke (1963)
Present state of psycholytic therap y and its possibilities
H. Leuner (1967)
10.1371/journal.pone.0009019
Psychedelics and the Human Receptorome
Thomas S. Ray (2010)
10.1097/00005053-199612000-00009
Drinking Careers: A Twenty-Five-Year Study of Three Navajo Populations
Paul G. Spicer (1996)
10.1001/archgenpsychiatry.2010.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
Nancy Diazgranados (2010)
10.1523/JNEUROSCI.17-08-02785.1997
5-HT2A Receptor-Mediated Regulation of Brain-Derived Neurotrophic Factor mRNA in the Hippocampus and the Neocortex
Vidita A Vaidya (1997)
10.1177/0269881110378371
The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study
Michael C. Mithoefer (2011)



This paper is referenced by
10.1177/0269881113513851
Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision
Peter Schuyler Hendricks (2014)
10.2174/15733998113099990003
Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada.
Gerald V. Thomas (2013)
10.1016/j.pnpbp.2015.03.002
Classic hallucinogens in the treatment of addictions
Michael P. Bogenschutz (2016)
10.1177/0269881114565144
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P. Bogenschutz (2015)
Classic hallucinogens in the treatment of addictions F
Michael P. Bogenschutz (2015)
10.25772/0YNR-6690
5-HT2B Receptor-mediated Cardiac Valvulopathy
Pallavi Nistala (2018)
10.1002/dta.1974
Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.
Simon D Brandt (2017)
10.1177/0269881118798610
The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women
Elena Argento (2018)
10.1556/2054.2018.005
Psychedelic therapy as a complementary treatment approach for alcohol use disorders
Peter Eischens (2018)
10.1007/7854_2016_464
Therapeutic Applications of Classic Hallucinogens.
Michael P. Bogenschutz (2018)
10.3389/fphar.2018.00897
Predicting Responses to Psychedelics: A Prospective Study
E. Haijen (2018)
10.4067/s0717-92272014000200005
Neurociencias y aplicaciones psicoterapéuticas en el renacimiento de la investigación con psicodélicos Neurosciences and psycotherapeutic applications in the psychedelic research renaissaince
Sandra Timmermann (2014)
10.1192/bjp.bp.114.148031
Can psychedelic compounds play a part in drug dependence therapy?
Ben Sessa (2015)
Keywords Psilocybin ! Hallucinogens ! Meditation ! Mystical experiences ! Neural model ! Default mode network ! Medial prefrontal cortex !
Frederick Streeter Barrett (2017)
10.1177/2045125316640440
Lysergic acid diethylamide: a drug of ‘use’?
Saibal Das (2016)
10.2174/1874473708666150107120522
A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects.
Mitchell B. Liester (2014)
Exploring the Therapeutic Potential of Psychedelics
Xavier Martínez Hernández (2018)
Therapeutic Induction of Altered States of Consciousness: Investigation of 1-20Hz Neurofeedback
Heather Hargraves (2017)
10.1177/0269881116642538
Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use
Zach Walsh (2016)
10.1111/dar.12985
Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada.
Elena Argento (2019)
10.1007/978-3-642-55125-3_99
Geschichte der Psychedelika in der Medizin
Ben Sessa (2018)
10.3109/00952990.2013.811513
A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment
Brittany Vasae Burdick (2013)
10.2174/1874473708666150107121331
Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
Albert Garcia-Romeu (2014)
10.1177/0269881116652578
The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging
Rafael Guimarães Dos Santos (2016)
10.1177/0269881119845793
Cessation and reduction in alcohol consumption and misuse after psychedelic use
Albert Garcia-Romeu (2019)
10.1177/0269881116677104
The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens
Clinton E. Canal (2017)
Psilocybin-assisted treatment for alcohol dependence
Michael P. Bogenschutz (2016)
10.1080/09540261.2018.1474088
Psychedelics and the new behaviourism: considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy
Zach Walsh (2018)
10.1016/j.physbeh.2015.01.032
Effects of ayahuasca on the development of ethanol-induced behavioral sensitization and on a post-sensitization treatment in mice
A J Oliveira-Lima (2015)
10.1177/0269881118780612
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
Tehseen Noorani (2018)
10.1016/j.neuropharm.2017.11.004
Why MDMA therapy for alcohol use disorder? And why now?
Ben Sessa (2018)
10.1177/0269881117714049
Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness
Matthias Forstmann (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar